Skip to main content
Search

Weill Cornell Medicine

4 related articles

Subscribe to updates
  1. arXiv

    Spatial transcriptomics skips dense grids: sparse 3D sampling plus three-way prediction reaches 0.361 PCC on HER2

    Volumetric spatial transcriptomics is expensive, and fixed-grid sampling measures redundant spots while missing informative regions in 3D tissue. STRATA co-optimizes sampling and prediction under a budget: on a 3D graph combining H&E morphology with single-cell priors, a reinforcement-learning agent picks morphologically sparse, transcriptomically informative spots, and a predictor fuses retrieval, regression and cross-layer imputation with per-spot weights. Across HER2, Breast, cSCC and a private Kidney cohort, STRATA has the highest PCC and lowest MSE; on HER2 its PCC is 0.361 and MSE 0.356, while the strongest-baseline figures stated in the text disagree with the table's baseline values, so that comparison is not quoted here.

  2. A single-cell velocity model you can perturb: it named three rescue targets for Arid1a-loss B cells, and mice confirmed all three

    DynaVelo puts RNA expression and transcription-factor motif accessibility from single-cell multiome data into one neural differential equation, learning a velocity field that can be perturbed rather than only drawn. In wild-type mouse germinal center B cells it recovers dark-zone cycling, the switch to the light zone and recycling; in Arid1a-heterozygous cells it nominated Ctcf, Stat3 and Bcl6 as rescue targets, and all three double-heterozygous mouse strains restored the dark-zone phenotype.

  3. Nature

    Brown fat tracks with fewer heart and psychiatric diagnoses in 101,243 patients, and AI pinpoints the axillary depot

    Among 101,243 patients at a cancer center, those with brown fat had fewer cardiovascular and psychiatric diagnoses; machine learning quantified brown fat activity in about 8,700 people, showing higher activity, especially in the axillary depot, tracked with lower odds of type 2 diabetes and coronary disease, and led to losartan as an activator in mice.

  4. medRxiv

    MES: A Multi-Agent Evidence Synthesis System for Medical Decision-Making

    This work presents MES, a multi-agent framework of six specialized agents (Supervisor, LiteratureMiner, RWD-Analyst, KG-Specialist, Statistician, SafeChecker) that integrates published literature and trial evidence, generates question-specific real-world evidence from real-world clinical data, and queries biomedical knowledge graphs while preserving source traceability; evaluated in two clinical use cases (an Alzheimer disease medication question with no matching literature and a septic shock beta-blocker question with inconsistent randomized evidence) and across 144 clinical queries spanning six evidence-based medicine categories, it produced structured reports that preserved source traceability, identified cross-source disagreement and communicated uncertainty, and its SafeChecker improv

You’re all caught up